

Resource Summary Report

Generated by [dkNET](#) on Aug 25, 2026

APC anti-mouse I-A/I-E

RRID:AB_313329

Type: Antibody

Proper Citation

BioLegend Cat# 107614, RRID:AB_313329

Antibody Information

URL: http://antibodyregistry.org/AB_313329

Proper Citation: BioLegend Cat# 107614, RRID:AB_313329

Target Antigen: I-A/I-E

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-mouse I-A/I-E

Description: This monoclonal targets I-A/I-E

Target Organism: mouse

Clone ID: Clone M5/114.15.2

Antibody ID: AB_313329

Vendor: BioLegend

Catalog Number: 107614

Alternative Catalog Numbers: 107613

Record Creation Time: 20250820T000759+0000

Record Last Update: 20250820T072724+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-mouse I-A/I-E.

No alerts have been found for APC anti-mouse I-A/I-E.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 53 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Pham LK, et al. (2026) NRF2-mediated inhibition of alveolar macrophage MHC II expression during Mycobacterium tuberculosis infection. Cell reports, 45(6), 117397.

Yao B, et al. (2026) Divergent tumor immunity determined by bacteria-cancer cell engagement. Cell, 189(6), 1748.

Hu Z, et al. (2026) Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors. Immunity, 59(7), 1928.

Diamond EL, et al. (2026) RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition. Cancer cell, 44(1), 203.

Brown JA, et al. (2026) Gut microbiota promotes immune tolerance at the maternal-fetal interface. Cell, 189(1), 196.

Abdelfattah N, et al. (2026) Male-biased Yap1-Cd276/B7-H3 axis for immune evasion in medulloblastoma. Cancer cell, 44(4), 760.

Guo J, et al. (2026) VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment. Cancer immunology research, 14(5), 718.

Zeng B, et al. (2026) HE4 drives PD-L1 expression in myeloid cells via IFN- γ -JAK-STAT3 signaling to promote tumor immune evasion. Cell reports. Medicine, 7(4), 102691.

Campisi M, et al. (2026) Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer. Cancer cell, 44(4), 858.

Kadam R, et al. (2026) Optineurin modulates mTORC2/AKT/STAT3 signaling to control MHC class II expression and adaptive immunity against HSV-1. Cell reports, 45(4), 117263.

Zhang ZD, et al. (2026) MITA/STING-driven CD38 induction in Siglec-Flow macrophages promotes regulatory T cell survival and non-small cell lung cancer progression. Developmental cell.

Mödl B, et al. (2026) TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis. *Cancer research*, 86(1), 80.

Skelly DA, et al. (2025) Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response. *Cell reports*, 44(5), 115698.

Qin T, et al. (2025) Treg-microglia partnership in the injured spinal cord preserves Treg cell function and regulates microglial cholesterol metabolism. *Neuron*.

Gong L, et al. (2025) Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy. *Cell*, 188(18), 5062.

Shi T, et al. (2025) CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases. *Cancer cell*.

Henriques-Oliveira L, et al. (2025) Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity. *Immunity*.

Hu X, et al. (2025) The transcription factor MEF2C restrains microglial overactivation by inhibiting kinase CDK2. *Immunity*, 58(4), 946.

Castellano M, et al. (2025) Ribonuclease activity undermines immune sensing of naked extracellular RNA. *Cell genomics*, 5(5), 100874.

Tang Z, et al. (2025) A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression. *Developmental cell*, 60(3), 379.